Phaseline

Targets › ABCC10

ABCC10 (ATP-binding cassette sub-family C member 10): drug programs, companies and trials

1 program from 1 company in 7 trials: 3 Phase 2, 2 Phase 4, 1 Phase 3, 1 Phase 1; Infectious disease; next expected readout Jun 2027.

ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds, and xenobiotics from cells. Lipophilic anion transporter that mediates ATP-dependent transport of glucuronide conjugates such as estradiol-17-beta-o-glucuronide and GSH conjugates such as leukotriene C4 (LTC4). (UniProt, Q5T3U5)

Open in Phaseline: the race on ABCC10, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesBictegravir
Human immunodeficiency virus type 1 integrase inhibitor
INTEGRASE, ABCC10Phase 3HIV-1-infection; HIV-1 Infection; HIV -1 Infection; HIV InfectionsJun 2027

Conditions

HIV-1-infection (4) HIV-1 Infection (1) HIV -1 Infection (1) HIV Infections (1)

Modalities

small molecule (1)

Companies

Gilead Sciences (1)

Related targets

INTEGRASE (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.